ZL-1310

Phase 3Small molecule

ZZai Lab (Shanghai) Co., Ltd.

ZL-1310 is one of 90 small molecule programs targeting Small Cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Small Cell Lung CancerRecruiting

Solid TumorRecruiting

SCLCRecruiting

Small Cell Lung CancerPhase 3

Recruiting

Solid TumorPreclinical

Recruiting

SCLCPhase 1

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

ZL-1310

ZZai Lab (Shanghai) Co., Ltd.

Phase 3

1 2

DATROWAY

Daiichi Sankyo

Preclinical

1 3

Fludara

Sanofi

Preclinical

1 4

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 5

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 6

Navmi

SSummit Therapeutics

Preclinical

1 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

1 8

Tulmimetostat

Novartis

Preclinical

1 9

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

2 10

Sacituzumab Govitecan-Hziy

Gilead

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

SCLC

NCT06179069

Q2 2028

PreclinicalRecruiting

Solid Tumor

NCT06885281

Q4 2028

Phase 3Recruiting

Small Cell Lung Cancer

NCT07218146

Q2 2030

PreclinicalNot yet recruiting

Small Cell Lung Cancer

NCT07707895

Clinical

Trials by Indication[1]

Small Cell Lung Cancer3 trials

A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer

Recruiting·ZZai Lab (Shanghai) Co., Ltd.·Phase 3·NCT07218146·480 enrolled

A Phase Ib/II, Open-label, Safety and Tolerability Trial of Obrixtamig in Combination With ZL-1310 in Patients With Poorly Differentiated NEC

Not yet recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Preclinical·NCT07707895·60 enrolled

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With ZL-1310 With or Without Anti-PD-L1 in Participants With Small Cell Lung Cancer

Recruiting· Amgen logo

Amgen·Phase 1·NCT07531095·160 enrolled

SCLC1 trial

An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Participants With Small Cell Lung Cancer

Recruiting·ZZai Lab (Shanghai) Co., Ltd.·Phase 1·NCT06179069·339 enrolled

Solid Tumor1 trial

A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors

Recruiting·ZZai Lab (Shanghai) Co., Ltd.·Preclinical·NCT06885281·166 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for ZL-1310. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ZL-1310 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ZL-1310. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zai Lab (Shanghai) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: ZZai Lab (Shanghai) Co., Ltd.

ZL-1310

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q2 2028

Q4 2028

Q2 2030

Trials by Indication[1]

Small Cell Lung Cancer3 trials

SCLC1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News